ResMed (RMD) Q4 2026 earnings review
Solid Top-Line Growth Masked by a Product Quality Charge
ResMed finished FY26 with a robust 9% reported revenue increase (8% constant currency) to a record $1.46 billion, driven by sustained global demand for sleep devices and masks. However, the bottom line tells a more complex story. GAAP gross margins compressed by 200 basis points due to a sudden $41.9 million field safety notification charge for Astral devices. Adjusting for this, non-GAAP EPS grew 16%, and non-GAAP gross margins expanded 90 basis points. Management is signaling immense confidence in its cash-generation engine, raising the dividend by 10% and guiding for an aggressive $1.85 billion in shareholder returns for FY27, while strategically divesting the lagging MatrixCare software business.
🐂 Bull Case
Sleep and Breathing Health revenue continues to grow at a high-single-digit clip globally (Americas +8%, Rest of World +10% CC), proving the core business is highly insulated from macro turbulence.
Management's commitment to return over $1.85 billion to shareholders in FY27 (up from $1.0 billion in FY26) puts a massive floor under the stock, supported by $1.6 billion in annual free cash flow.
🐻 Bear Case
The $41.9 million Astral field safety notification wiped out GAAP operating profit growth for the quarter. Investors will need assurance this is an isolated incident, not a systemic quality control failure.
Operating cash flow dropped 16% YoY in Q4 to $455 million, heavily driven by an unfavorable build in working capital (accounts receivable).
⚖️ Verdict: 🟢
Bullish. The 42 million dollar safety charge is a negative surprise, but underlying Non-GAAP margins expanded and core device/mask growth remains ironclad. Selling the lagging software unit to return more cash to shareholders is a highly accretive strategic move.
Key Themes
Massive Acceleration in Capital Returns
ResMed is shifting its capital allocation strategy into overdrive. After returning $1.0 billion in FY26 (a 70% YoY increase), management is guiding for over $1.85 billion in repurchases and dividends for FY27. This represents more than 100% of the company's FY26 Free Cash Flow ($1.65B), indicating management views the stock as deeply undervalued and is willing to leverage its pristine balance sheet.
Astral Device Safety Notification Wrecks GAAP Margins
A severe specific data point contradicting the otherwise positive margin narrative: ResMed booked a $41.9 million field safety notification expense related to its Astral life support ventilators. This charge directly drove GAAP gross margins down 200 basis points YoY to 58.8% and caused GAAP operating income to contract 1%. While classified as non-GAAP adjustments, sudden safety costs raise competitive risks—especially given that ResMed has historically capitalized heavily on rival Philips' multi-year safety recall catastrophe.
Residential Care Software (RCS) Segment Lags
RCS remains the persistent anchor on ResMed's top line, continuing a decelerating trend. Q4 revenue grew a meager 2% in constant currency (down from 4% in Q3 and 5% in Q2), sharply underperforming the core hardware divisions. Management is finally acting on this prolonged weakness by announcing the divestiture of the MatrixCare business, aiming to cut dead weight and refocus on high-margin sleep tech.
Masks and Accessories Driving Margin and Mix
The high-margin Masks and Other category continues to be a growth engine, up 11% globally (10% CC) to $542 million in Q4. Product innovation is playing a central role, with the continued global rollout of the AirTouch F30i Comfort mask into new markets like Brazil and Chile protecting pricing power and driving patient compliance.
Expanding the Digital Diagnostic Funnel (Macro Consumer Trend)
ResMed continues to exploit broader macro health trends to widen the top of its patient funnel. Building on historical tailwinds from GLP-1 awareness, the company announced a new strategic partnership with the consumer wearable brand OURA. This tech-integration specifically targets the massive pool of undiagnosed sleep apnea sufferers by using consumer sleep-tracking data to educate and route users directly into clinical pathways.
Portfolio Expansion into Restless Leg Syndrome
With the successful close of the $340 million Noctrix Health acquisition, ResMed officially expands its portfolio beyond sleep apnea and into Restless Leg Syndrome (RLS). The FDA De Novo classified wearable therapeutics offer a high-margin, high-growth avenue that leverages ResMed's existing relationships with sleep physicians.
Other KPIs
Reversing. Despite higher net income, Q4 operating cash flow fell 16% YoY from $539 million in 25Q4. The cash flow statement reveals this was primarily driven by negative shifts in working capital, specifically a $37.2 million drag from accounts receivable and $33.8 million from inventory buildup, compared to much lighter impacts in the prior year. This signals minor friction in collections or timing of billings.
Stable. Up 90 basis points compared to 25Q4 (61.4%), reflecting ongoing execution in the productivity pipeline, scale benefits, and supply chain normalization. However, it decelerated slightly on a sequential basis from the 62.8% high-water mark reached in 26Q3.
Guidance
Accelerating dramatically. The target represents an 85% increase over the $1.0 billion returned in FY26. Given the $0.66 quarterly dividend implies roughly $380M in annual dividend payouts, the math suggests ResMed intends to execute approximately $1.47 billion in share repurchases in the coming fiscal year.
Accelerating. Raised 10% from the previous quarterly payout of $0.60 per share, showcasing confidence in recurring cash generation despite near-term restructuring and safety notification costs.
Key Questions
Astral Device Remediation
You recorded a nearly $42 million field safety notification expense for Astral devices. Are these costs strictly backward-looking, or should we model for ongoing margin drag as you remediate the issue? Is there any risk of regulatory action?
MatrixCare Divestiture Impact
With the sale of MatrixCare expected to close in Q1, what is the expected revenue and margin profile of the remaining Residential Care Software segment? Should we view this as a complete exit from the facility-based software space?
Working Capital Reversal
Operating cash flow declined 16% in Q4 despite record revenues, largely due to accounts receivable and inventory builds. Is this simply a timing issue related to late-quarter sales, or are you seeing a slowdown in channel payments?
Capital Return Flexibility
Your FY27 capital return guidance of over $1.85 billion exceeds your FY26 free cash flow. Does this signal an intent to take on leverage, or are you modeling a massive step-up in operating cash flow for the coming year?